1. Scrip
  3. >>Immunological

Inovio surprised by Roche returning prostate cancer immunotherapy

 
• By Eleanor Malone

The CEO of Inovio Pharmaceuticals has said the decision of its partner Roche to return rights to its prostate cancer immunotherapy "was a surprise to us". Dr Joseph Kim, Inovio's president and CEO, told Scrip that the company had no idea the collaboration was about to be terminated when Inovio reported Q3 results on 10 November and said it was expecting to begin Phase I trials of the preclinical DNA vaccine with Roche in 2015. "We were told on Friday [14 November] and announced it first thing Monday [17 November]," he said. "I believe it was a surprise to the Roche development team as well," he added.

The CEO of Inovio Pharmaceuticals has said the decision of its partner Roche to return rights to its prostate cancer immunotherapy "was a surprise to us". Dr Joseph Kim, Inovio's president and CEO, told Scrip that the company had no idea the collaboration was about to be terminated when Inovio reported Q3 results on 10 November and said it was expecting to begin Phase I trials of the preclinical DNA vaccine with Roche in 2015. "We were told on Friday [14 November] and announced it first thing Monday [17 November]," he said. "I believe it was a surprise to the Roche development team as well," he added.

Roche licensed the early-stage prostate cancer immunotherapy from Inovio Pharmaceuticals in 2013

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.